Abstract
Evidence suggests that the rs11615 (C>T) polymorphism in the ERCC1 gene may be a risk factor for gynecological tumors. However, results have not been consistent. Therefore we performed this meta- analysis. Eligible studies were identified by search of PubMed, MEDLINE and Chinese National Knowledge Infrastructure (CNKI). Odds ratios (ORs) and 95% confidence intervals (CIs) were applied to assess associations between rs11615 (C>T) and gynecological tumor risk. Heterogeneity among studies was tested and sensitivity analysis was applied. A total of 6 studies were identified, with 1,766 cases and 2,073 controls. No significant association was found overall between the rs11615 (C>T) polymorphism and gynecological tumor susceptibility in any genetic model. In further analysis stratified by cancer type, significantly elevated ovarian cancer risk was observed in the homozygote and recessive model comparison (TT vs CC: OR=1.69, 95% CI=1.03-2.77, heterogeneity=0.876; TT vs OR=1.72, 95% CI=1.07-2.77, heterogeneity=0.995). The results of the present meta-analysis suggest that there is no significant association between the rs11615 (C>T) polymorphism and gynecological tumor risk, but it had a increased risk in ovarian cancer.
Highlights
Gynecological tumor is a one of the public health problem around the world
We found no significant association of the rs11615 (C>T) polymorphism with overall cancer risk in any of four models
It has been reported that a number of single nucleotide polymorphisms (SNPs) of nucleotide excision repair (NER) genes can alter the function of the respective genes, contributing to inter-individual variations of DNA repair capacity and a reduced DNA repair capacity may predispose an individual to cancer (Dunlop et al, 1997; Cheng et al, 1998; Park et al, 2002; Marin et al, 2004; Chen et al, 2007)
Summary
Gynecological tumor is a one of the public health problem around the world. Some studies identified that genetics play a vital role in determining cancer risk and various genetic variations have been identified to increase cancer risk (Goode et al, 2002; He et al, 2008). Some studies have investigated the association between ERCC1 polymorphisms and gynecological tumor risk, but results are inconclusive and inconsistent. We conducted this meta-analysis to synthesize the results of these studies and to establish a more durable conclusion. Evidence suggests that the rs11615 (C>T) polymorphism in the ERCC1 gene may be a risk factor for gynecological tumors. No significant association was found overall between rs11615 (C>T) polymorphism and gynecological tumors susceptibility in any genetic model. Conclusion: The results of the present meta-analysis suggest that there is no significant association between the rs11615 (C>T) polymorphism and gynecological tumor risk, but it had a increased risk in ovarian cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
